<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>MRC Centre for Inflammation Research</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/2B421EBD-F572-4244-A9EB-02E8356AC8BD"><gtr:id>2B421EBD-F572-4244-A9EB-02E8356AC8BD</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>Anthony</gtr:otherNames><gtr:surname>Gibbons</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601409"><gtr:id>012363CF-93B7-4F2B-9DB3-5D0B16CE0CF4</gtr:id><gtr:title>The functional role of macrophages in the progression and resolution of lung fibrosis.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0601409</gtr:grantReference><gtr:abstractText>Tissue scarring (fibrosis) is the common endpoint in many inflammatory disorders of the lung. In progressive lung fibrosis there is an inexorable decline in exercise tolerance followed by respiratory failure and death. There is no effective treatment. The macrophage is an inflammatory cell that is associated with lung fibrosis. Recent studies in the liver and kidney indicate that macrophages are critical to the regulation of scarring. I propose to conduct a series of experiments to determine the role that macrophages (both those already in the lung and those derived from the circulation and bone marrow) play in the progression and resolution of fibrosis using well established mouse models of lung fibrosis. I will then determine whether the manipulation of macrophages of bone marrow origin can be used to alter, and ultimately reverse, fibrosis in the lung. I believe this work will be important to inform the rational design of targeted therapies for lung fibrosis based on macrophage cell therapy and potentially for other life threatening lung conditions, characterised by inflammation and scarring such as the acute respiratory distress syndrome (ARDS) that occurs in patients in intensive care.</gtr:abstractText><gtr:technicalSummary>I wish to investigate the functional role of the macrophage in murine models of lung fibrosis. 

Studies in murine models have identified a reversible component to lung fibrosis. Macrophages are key cells in both the genesis and resolution of fibrosis in many tissues; recently it was shown that a proportion of alveolar macrophages are of bone marrow (BM) origin. 

My first goal is to define functionally the role of the macrophage at key stages in the progression and resolution of lung fibrosis by applying a transgenic mouse model of toxin mediated macrophage depletion (DTR mouse) to murine models of lung fibrosis (1 reversible, 1 progressive).

Next I will determine the relative importance of indigenous versus BM-derived alveolar macrophages in the regulation of lung fibrosis. Mice (wild type or DTR) will receive crossover BM transplants prior to the induction of lung fibrosis. Selective depletion of either the resident alveolar macrophage or the circulating BM-derived macrophage will enable us to demonstrate the relative importance of these macrophage populations in the control of fibrosis. 

Lastly I will determine whether manipulation of macrophages can influence the fibrotic lung response. In the first instance we will study MMP-2 which regulates matrix turnover and myofibroblast proliferation in lung fibrosis. By performing BM transplants from MMP-2 knockout mice prior to lung fibrosis induction, we will determine whether manipulation of macrophages can be used to modify pulmonary fibrosis

At the end of this fellowship I believe that I will have established a series of data that will add significantly to the body of work that already exists on lung injury and repair. It is hoped that this research project will inform the design of targeted treatments for pulmonary fibrosis (and potentially other life threatening pulmonary disorders characterised by inflammation and repair such as ARDS).</gtr:technicalSummary><gtr:fund><gtr:end>2010-05-14</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-05-15</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>238654</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>This model of lung fibrosis has been optimised in house and is now in widespread use within our institute, and we have given advice to other institutes on how to use if effectively.</gtr:description><gtr:id>2F824594-65DA-4316-B945-FAC88314D1A1</gtr:id><gtr:impact>The model is safe, reproducible, and effective.</gtr:impact><gtr:outcomeId>4FBD8ADB7EA</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Bleomycin model</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Assay of total lung collagen</gtr:description><gtr:id>D14FA620-150A-460B-AA4B-502D4DA8151C</gtr:id><gtr:impact>Several groups in our institute are using this assay as the primary outcome measure for lung fibrosis.</gtr:impact><gtr:outcomeId>CF505BA4B19</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Sircol assay</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The model of adenoviral TGFbeta lung injury was developed for the first time in the UK.</gtr:description><gtr:id>267BC721-5747-4E14-B5C0-EA5EE0649A10</gtr:id><gtr:impact>Allows use of another safe, reproducible and effective model to investigate lung fibrosis</gtr:impact><gtr:outcomeId>B02BA4FC93B</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>adenoviral TGFbeta model</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>F2D1EBE9-F86C-44E1-8734-BB84282F85FE</gtr:id><gtr:title>Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/482af3eb67f4ca194e8027d61bd41d29"><gtr:id>482af3eb67f4ca194e8027d61bd41d29</gtr:id><gtr:otherNames>Gibbons MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>Rm3RKraB4sm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3ED1EF9D-682E-43F1-B9D2-FB880B8CE544</gtr:id><gtr:title>Monocytes control second-phase neutrophil emigration in established lipopolysaccharide-induced murine lung injury.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8ce3ba620de702c23f727037840690f"><gtr:id>b8ce3ba620de702c23f727037840690f</gtr:id><gtr:otherNames>Dhaliwal K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>pm_15389_29_22822022</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>140D1461-C738-4B6B-86E8-A07B4C049DD1</gtr:id><gtr:title>Regulation of transforming growth factor-?1-driven lung fibrosis by galectin-3.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63c7bce3bce4e2b8e6a17cf6e1e4bbd6"><gtr:id>63c7bce3bce4e2b8e6a17cf6e1e4bbd6</gtr:id><gtr:otherNames>Mackinnon AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>pm_15389_29_22095546</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601409</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>67</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>